Mylan told us “The decision to close the site comes after a careful assessment of bringing the two businesses together as part of our integration process and is consistent with our ongoing efforts to operate our businesses as efficiently as possible.”
The firm employs 90 people at the facility, all of whom will be offered “packages that include severance pay, benefit continuation, and outplacement counselling and assistance.”
Manufacturing operations at the site are expected to have ceased by 2018.
According to Meda’s website, the facility produces the analgesic Soma (carisoprodol), the anti-allergy drug Astepro (azelastine) and dietary supplements belonging to the Geritol range.
Mylan stressed that “products manufactured in Decatur will continue to be manufactured in the US.”
Integration
Mylan has made a number of cutbacks at Meda since the takeover last year.
In December it closed the Swedish drug firm’s sales office in Somerset New Jersey.
More recently, the firm has reduced Meda's workforce at sites in Morgantown, West Virginia, Washington, DC, St. Albans City, Vermont., and Greensboro, North Carolina.